Oncophage

February 5, 2012

Ipilimumab Approval Highlights Immunotherapy Renaissance

March 25, 2011 By MD Becker Partners Leave a Comment

mab_slide

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.

Filed Under: Articles Tagged With: AGEN, Agenus, Allovectin-7, Amgen, AMGN, Antigenics, AVAX, AVAX Technologies, AVXT.PK, Bavarian Nordic, BIIB, Biogen Idec, BiovaxID, Biovest International, BioVex, BMY, Bristol-Myers Squibb, BVTI, CancerVax, Canvaxin, CDX-110, Celldex Therapeutics, CLDX, Corixa, Dendreon, DNDN, GlaxoSmithKline plc, GMK vaccine, GSK, ipilimumab, Lucanix, MAGE-A3 ASCI, Melacine, MVAX, Novarx, Oncophage, Oncothyreon, OncoVex, ONTY, Oxford BioMedica, PGNX, Progenics Pharmaceuticals, PROSTVAC, Rituxan, rituximab, Stimuvax, TG4010, transgene, Trovax, Vical, VICL, William Coley, Yervoy

Agenus Inc.

January 1, 2011 By MD Becker Partners Leave a Comment

Company Spotlight

Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. With our strong platform technologies, multiple product candidates are advancing through the clinic. The most suitable patient populations to benefit from our novel vaccine approach have been defined. View the company’s fact sheet (PDF)

Filed Under: Company Spotlights Tagged With: AGEN, Agenus, cancer immunotherapy, HSPPC-96, Oncophage, prophage, QS-21

Cancer Vaccine Therapies: Failures and Future Opportunities

April 7, 2010 By MD Becker Partners 3 Comments

FIGURE 1: FDA APPROVAL OF CANCER MABS FROM 1997-2010

(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active immunization, [...]

Filed Under: Articles Tagged With: active immunotherapy, AGEN, allogeneic, Allovectin-7, American Society for Clinical Oncology, Antigenics, Arzerra, ASCO, autologous, Bavarian Nordic, BIIB, Biogen Idec, Biologics License Application, biotechnology, BiovaxID, Biovest International, BMY, Bristol-Myers Squibb Company, BVTI, cancer vaccine, CD20, CDX-110, Celldex Therapeutics, CTLA-4, Dendreon, dendritic cells, DNDN, EGFRvIII, Genmab A/S, GlaxoSmithKline, GM-CSF, gp100, GSK, GVAX, immunotherapy, ipilimumab, life sciences, lung cancer, MAGE-3, MAGE-A3 ASCI, MD Becker Partners, melanoma, monoclonal antibodies, NCI, NHL, non-Hodgkin’s Lymphoma, NSCLC, ofatumumab, Oncophage, passive immunotherapy, PDUFA, PFE, Pfizer, prostate cancer, prostatic acid phosphatase, PROSTVAC, Provenge, RHHBY, Rituxan, rituximab, Roche Group, sipuleucel-T, TRICOM, vaccine, Vical, VICL